Wednesday, June 20, 2018 12:21:10 PM
They may not have the finances or capability to do all the trials necessary or build a Salesforce to sell this product. This company would be better served to partner with a Pharma co that has the expertise in this area and share the risk. This will be a 4 billion market with no approved products. This will be ripe for a partner with pockets to give them a $500 million grant based on milestones to help them develop this product. We need to see some initial efficacy for this to be an attractive risk for pharma. I can see something like this happening end of 19 or early 20 as they progress through development.
Recent CVSI News
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 02:36:49 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:21:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 01:32:15 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM